People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | — | Biotechnology | Growth/Late | $527.8M | $5.7B | 2014 |
| Kura Oncology, Inc. | — | Biotechnology | Series D+ | $241.7M | $1.9B | 2015 |
| Kura Operations, Inc. | — | Biotechnology | Series C | $63.4M | $2.5B | 2015 |
| Montara Therapeutics, Inc. | — | Biotechnology | Series B | $28.0M | $107.6M | 2025 |
| Intellikine, Inc. | — | Biotechnology | Series B | $16.0M | $636.4M | 2009 |
| Centrose LLC | — | Pharmaceuticals | Series B | $5.2M | $3.4M | 2013 |
| Araxes Pharma, LLC | — | Pharmaceuticals | Seed | $1.0M | $39.6M | 2012 |
TROY WILSON at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside TROY WILSON on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| HEIDI HENSON | 3 | 5 |
| YI LIU | 2 | 4 |
| PINGDA REN | 2 | 3 |
| ANTONIO GUALBERTO | 2 | 2 |
| ANNETTE NORTH | 2 | 2 |
| Michael Martin | 1 | 11 |
| Todd Brady | 1 | 7 |
| Michael F. Powell | 1 | 6 |
| Faheem Hasnain | 1 | 5 |
| Roderick Wong | 1 | 4 |
| Raymond F. Schinazi | 1 | 4 |
| Mary Szela | 1 | 3 |
| Zachary Hill | 1 | 2 |
| Nicholas Hertz | 1 | 2 |
| Teresa Bair | 1 | 2 |
| DIANE PARKS | 1 | 2 |
| Raymond S. Schinazi | 1 | 2 |
| Karl D. Handelsman | 1 | 2 |
| Ken Haas | 1 | 2 |
| P. Kent Hawryluk | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.